ADMA Biologics Inc Common Stock (ADMA)

FairStock Score: 57/100 — STEADY

Key Financials

Strengths

• High return on equity of 35.6% demonstrating efficient capital deployment
• Altman Z-Score of 11.6 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 18.4% demonstrates strong top-line momentum

Concerns

• Trades significantly above Graham Number ($5) with negative 115% margin of safety—limited downside protection

AI Analysis

ADMA Biologics Inc Common Stock is a small-cap healthcare company valued at $2.6 billion. The business generates $510 million in annual revenue with a 9.7% net margin. From a quality standpoint, ADMA shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 11.6 confirms fortress-level solvency. On valuation, the stock is reasonably priced at 18.5x earnings, with trades far above its Graham Number ($5) with no margin of safety. Growth dynamics show revenue growing at 18.4% and profit growth of -55.9%. Our composite FairStock Score of 57/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

ADMA's 18% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer